日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Empagliflozin improves beta cell function independently of relief of glucotoxicity in patients with type 2 diabetes: results from a randomised cross-over study with insulin as comparator

恩格列净可改善 2 型糖尿病患者的 β 细胞功能,且与缓解葡萄糖毒性无关:一项以胰岛素为对照的随机交叉研究结果

Thirumathyam, Roopameera; Richter, Erik A; van Hall, Gerrit; Andersen, Nicoline R; Madsen, Per L; Holst, Jens J; Madsbad, Sten; Jørgensen, Nils B

The role of empagliflozin-induced metabolic changes for cardiac function in patients with type 2 diabetes. A randomized cross-over magnetic resonance imaging study with insulin as comparator

恩格列净诱导的代谢变化对2型糖尿病患者心脏功能的影响:一项以胰岛素为对照的随机交叉磁共振成像研究

Thirumathyam, Roopameera; Richter, Erik Arne; van Hall, Gerrit; Holst, Jens Juul; Fenger, Mogens; Gøtze, Jens P; Dixen, Ulrik; Vejlstrup, Niels; Madsbad, Sten; Madsen, Per Lav; Jørgensen, Nils Bruun